**Supplementary Table 1.** Characteristics of patients on AZA and MP who developed a thiopurine-induced acute pancreatitis.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Gender | Disease | Age (years) | Drug | Dose (mg) | Dose (mg/kg) | Days to TIAP | Maximal amylase (ref) | Maximal lipase (ref) | Maximal C-reactive protein level (mg/l) | Alternative treatment strategy |
| M | CD | 57 | MP | 50 | 0.61  | 21 | - | 207 (51) | 51  | Steroids |
| M | CD | 59 | MP | 150 | 1.22  | 31 | - | 216 (51) | 135 | 6-thioguanine |
| M | CD | 27 | AZA | 50 | 0.65  | 20 | 704 (100) | - | 211 | Unknown |
| M | UC | 24 | AZA | 200 | 2.08  | 16 | 735 (100) | 573 (59) | 102 | Steroids |
| F | UC | 61 | MP | 75 | 1.25  | 16 | 354 (200) | 897 (59) | 11a | MTX |
| F | CD | 19 | AZA | 125 | 2.19  | 21 | 109 (100) | 296 (59) | 77 | MP 50mg b |
| M | CD | 28 | AZA | 175 | 1.99  | 21 | - | 553 (60) | 100 | Infliximab |
| F | CD | 53 | AZA | 150 | 2.10  | 18 | - | 756 (60) | 86 | Infliximab |
| F | CD | 58 | AZA | 150 | 2.34  | 22 | - | 1247 (60) | 29 | Infliximab |
| F | CD | 48 | AZA | 200 | 2.16  | 21 | - | 849 (60) | 324 | MTX |
| F | CD | 42 | AZA | 125 | 2.21  | 21 | 395 (100) | - | 15 | 5-ASA |
| F | CD | 55 | AZA | 200 | 2.50  | 14 | 605 (100) | - | 212 | Steroids |
| F | CD | 40 | AZA | 150 | 2.27  | 15 | 888 (100) | - | 146 | Surgery |
| M | CD | 28 | AZA | 175 | 2.50  | 23 | 141 (200) | 918 (59) | 129 | MTX |

All patients stopped the initial thiopurine because of the pancreatitis. The reference values for amylase and lipase of the corresponding laboratories are provided within the brackets. a measured six days after the maximal lipase value. b This patient was rechallenged with MP, however this was stopped after one day due to fever.

5-ASA, 5-aminosalicylic acid; AZA, azathioprine; CD, Crohn’s disease; F, female; M, male; MP, mercaptopurine; MTX, methotrexate; ref, reference value of local laboratory; TIAP, thiopurine induced acute pancreatitis; UC, ulcerative colitis